Mirum Pharmaceuticals, Inc.
MIRM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2 | $1 | $1 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $2 | $1 | $1 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 80.8% | 141.8% | 302.7% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 75.8% | 74.8% | 83.9% | 90.1% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -14.5% | -73.2% | -159.4% | -341.7% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -26.1% | -87.7% | -176% | -438.9% |
| EPS Diluted | -1.85 | -4 | -4.02 | -2.77 |
| % Growth | 53.8% | 0.5% | -45.1% | – |
| Operating Cash Flow | $0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | -$0 | -$0 | -$0 |